The glucagon receptor activation at 8mg and above drives significant lipolysis and fat oxidation, which, combined with adequate protein intake and resistance training , may preserve lean tissue better than lower doses
Several mid-stage trials will read out in 2025 to provide important proof points for novel MoAs and their potential for differentiation, e.g., Lillys bimagrumab (activin/myostatin type II receptor inhibitor) in combination with semaglutide, aiming to deliver weight loss while preserving muscle mass (phase 2b)
Safety is a priority for any new drug
AM833 is a novel agonist of calcitonin family G protein-coupled receptors: pharmacological comparison with six selective and nonselective agonists
Glucose-induced and ChREBP: MLX-mediated lipogenic program promotes hepatocellular carcinoma development
This product and all related information have not been evaluated by the U.S